Novotarg is a novel bispecific antibody that demonstrates anti-tumor activity in mouse lymphoma models¹.

Novotarg promotes the death of cancer cells by selectively targeting both CD20, a known target in blood-borne cancer, and CD95 which induces cell death. Tests in mouse models have demonstrated that Novotarg provides superior anti-tumor activity to anti-CD20 alone¹.

The patented bispecific antibody technology has the potential to allow the design of superior antibody therapeutics with two antigen binding sites. The resulting antibodies have increased selectivity for the respective targets, potentially providing increased efficacy and safety. This bispecific concept is also applicable to a variety of different target antigens, such as CD19, CD40, tenascin and NG2².


  1. Nalivaiko K et al. A Recombinant Bispecific CD20×CD95 Antibody with Superior Activity Against Normal and Malignant B-cells. Mol Ther. 2016;24:298–305.
  2. Herrmann T et al. Construction of Optimized Bispecific Antibodies for Selective Activation of the Death Receptor CD95. Cancer Res. 2008;68:1221-7.